Hanmi Science Co Stock

Hanmi Science Co Liabilities 2024

Hanmi Science Co Liabilities

438.66 B KRW

Ticker

008930.KS

ISIN

KR7008930000

In 2024, Hanmi Science Co's total liabilities amounted to 438.66 B KRW, a 13.95% difference from the 384.94 B KRW total liabilities in the previous year.

Hanmi Science Co Aktienanalyse

What does Hanmi Science Co do?

Hanmi Science Co Ltd is a South Korean company specializing in the manufacturing of pharmaceutical products, biologics, and medical devices. The company was founded in 1973 as a chemical company and obtained the license for drug manufacturing in 1990, expanding its product range to include pharmaceuticals. Today, the company's business model includes three main areas: research and development, manufacturing and sales of drugs, and sales of medical devices. Hanmi aims to develop and produce innovative and high-quality products to improve people's health worldwide. In the field of research and development, Hanmi Science is a leading company. It specializes in the research and development of novel drugs and biologics. The company has an impressive track record in the development and marketing of innovative drugs for the treatment of diabetes, cancer, and rare diseases. This includes a range of biosimilars produced using biotechnological methods that are more affordable compared to original medical substances. Hanmi also has a state-of-the-art production infrastructure that meets the highest quality standards and ensures reliable supply. In the field of drug manufacturing, the company produces generics and biosimilars that are sold in more than 50 countries worldwide. Hanmi also specializes in the production of chemotherapeutics and parenteral drugs that have proven efficacy and safety. The medical device sales division focuses on marketing high-quality medical devices, including diagnostic and monitoring devices used in the medical field. Hanmi also distributes a range of medical consumables, including transfusion sets, syringes, infusion sets, and catheters. Hanmi Science Co Ltd offers a wide range of products that can be categorized into various categories. Among the pharmaceutical products are antidiabetic drugs, anticancer agents, antidepressants, antibiotics, antiviral medications, and products for the treatment of rare diseases. The portfolio also includes biosimilars of botulinum toxin, insulin, and humiderm among the biologics. Overall, Hanmi Science Co Ltd holds a strong position in the South Korean market and has also established a good reputation internationally. With its focus on research and development and the production of high-quality drugs and medical devices, the company has a promising future. Hanmi Science Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Hanmi Science Co's Liabilities

Hanmi Science Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Hanmi Science Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Hanmi Science Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Hanmi Science Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Hanmi Science Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Hanmi Science Co stock

What is the level of liabilities of Hanmi Science Co this year?

Hanmi Science Co has a debt balance of 438.66 B KRW this year.

What were the liabilities of Hanmi Science Co compared to the previous year?

The liabilities of Hanmi Science Co have increased by 13.95% increased compared to the previous year.

What are the consequences of high debt for investors of Hanmi Science Co?

High liabilities can pose a risk for investors of Hanmi Science Co, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Hanmi Science Co?

Low liabilities mean that Hanmi Science Co has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Hanmi Science Co affect the company?

An increase in liabilities of Hanmi Science Co can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Hanmi Science Co affect the company?

A decrease in the liabilities of Hanmi Science Co can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Hanmi Science Co?

Some factors that can influence the liabilities of Hanmi Science Co include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Hanmi Science Co so important for investors?

The liabilities of Hanmi Science Co are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Hanmi Science Co take to modify the liabilities?

To change its liabilities, Hanmi Science Co can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Hanmi Science Co pay?

Over the past 12 months, Hanmi Science Co paid a dividend of 200 KRW . This corresponds to a dividend yield of about 0.59 %. For the coming 12 months, Hanmi Science Co is expected to pay a dividend of 200 KRW.

What is the dividend yield of Hanmi Science Co?

The current dividend yield of Hanmi Science Co is 0.59 %.

When does Hanmi Science Co pay dividends?

Hanmi Science Co pays a quarterly dividend. This is distributed in the months of January, January, January, July.

How secure is the dividend of Hanmi Science Co?

Hanmi Science Co paid dividends every year for the past 7 years.

What is the dividend of Hanmi Science Co?

For the upcoming 12 months, dividends amounting to 200 KRW are expected. This corresponds to a dividend yield of 0.59 %.

In which sector is Hanmi Science Co located?

Hanmi Science Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hanmi Science Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hanmi Science Co from 8/14/2024 amounting to 100 KRW, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Hanmi Science Co pay the last dividend?

The last dividend was paid out on 8/14/2024.

What was the dividend of Hanmi Science Co in the year 2023?

In the year 2023, Hanmi Science Co distributed 196.078 KRW as dividends.

In which currency does Hanmi Science Co pay out the dividend?

The dividends of Hanmi Science Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Hanmi Science Co

Our stock analysis for Hanmi Science Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hanmi Science Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.